Clinical Trials Sponsored by Cullinan Pearl

Total 83 results

Cullinan Oncology Inc.

Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS) | Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States
Cullinan Oncology Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Singapore, Hong Kong, Netherlands, Japan, China, Korea, Republic of
Cullinan Oncology Inc.

Recruiting

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

NHL | NHL, Relapsed, Adult

United States
Cullinan Therapeutics Inc.

Recruiting

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Advanced Solid Tumor

United States, Spain, Australia, Poland
Pearl Network

Completed

Assessing the Effects of Three Oral Care Regimens

Gingivitis | Dental Plaque

United States
Pearl Therapeutics, Inc.

Completed

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Pearl Therapeutics, Inc.

Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Japan
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Withdrawn

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

COPD

United States
Pearl Therapeutics, Inc.

Completed

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

COPD

United States, Austria, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Peru, Russian Federation, Hungary, China, Taiwan, Australia, Japan, Argentina, South Africa, Belgium, Czechia, Serbia, Poland, Mexico, New... and more
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

COPD

Belgium
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

COPD

United States
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Cullinan Therapeutics Inc.

Not yet recruiting

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Cullinan Oncology Inc.

Recruiting

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Maggie's Pearl, LLC

Active, not recruiting

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Pmm2-CDG | Phosphomannomutase 2 Deficiency | Phosphomannomutase 2 Congenital Disorder of Glycosylation | Phosphomannomutase II Congenital Disorder of Glycosylation | Phosphomannomutase II Deficiency

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

COPD

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Pearl Therapeutics, Inc.

Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PT009001)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
Pearl Therapeutics, Inc.

Completed

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Pearl Therapeutics, Inc.

Completed

PK Study of PT003 and PT001 in Japanese Healthy Subjects

COPD

United States
Pearl Therapeutics, Inc.

Completed

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States

3

Subscribe